PFE PFIZER INC

Price Chart

Executive Summary

CICC initiated coverage on Pfizer at Outperform with a $33 price target, implying 27% upside from the current $25.96. The call is contrarian: 20 of 36 analysts rate PFE Buy/Strong Buy, but 17 rate Hold and 3 are Sell/Strong Sell — a split consensus. CICC's track record is 55% accurate on 31 calls with a 1.4% average return, placing it below top-tier firms like Morgan Stanley (71% on 7 calls, 4.2% avg return). The mean target is $29.11, so CICC's $33 is above consensus. Momentum is flat — no upgrades or downgrades in the last 30 days — and EPS revisions are mixed (up 8, down 6 for the current quarter). Insider trades are absent, but a small congressional buy (Ro Khanna, $1K-$15K) is a weak bullish signal. Institutional activity is mixed: Norges Bank added a massive new position ($1.83B) while Renaissance Technologies exited. Short interest is elevated at 56.2% of TRF volume, suggesting bearish positioning. Bottom line: CICC's initiation is a modestly bullish contrarian call from an average-accuracy firm, but the high short interest and mixed institutional flows warrant caution.

Impact Score

Consensus & Targets

Of 36 analysts covering PFE: 5 Strong Buy, 11 Buy (44% bullish), 17 Hold (47% neutral), 2 Sell, 1 Strong Sell (8% bearish). The consensus is effectively neutral-to-slightly-bullish, with nearly half rating Hold. CICC's Outperform initiation is a bullish outlier relative to the consensus.

Current price: $25.96. Mean target: $29.11 (implied upside 12.1%). Median: $28 (7.9% upside). High: $36 (38.7% upside). Low: $24 (7.5% downside). CICC's $33 target is 13.4% above the mean and 17.9% above the median, placing it in the top quartile of analyst targets.

Recent Analyst Activity

No upgrades or downgrades in the last 30 days — a quiet period. EPS revisions are mixed: for the current quarter (+1q), 8 revisions up vs 6 down in the last 30 days, but the EPS estimate has ticked down from $0.858 to $0.851. For the full year (0y), 11 up vs 6 down, with EPS edging up from $2.963 to $2.967. Overall, estimates are modestly positive but not strongly trending.

Firm Track Record — CICC

CICC accuracy: 55% on 31 calls | avg return: 1.4%

Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 7 firms with ≥5 scored calls.

CICC has a 55% accuracy rate on 31 calls with a 1.4% average return, ranking below top-tier firms like Morgan Stanley (71% on 7 calls, 4.2% avg return) and B of A Securities (67% on 3 calls, -0.1% avg return). CICC is above Cantor Fitzgerald (59%, 1.8%) but below Citigroup (50%, -5%) and Barclays (50%, -1.2%). Best performing firm on PFE: Morgan Stanley (71%, 4.2%). Worst: Guggenheim (40%, -1.4%) and UBS (40%, -2.7%).

Earnings Estimates

Cross-Platform Signals

Insider trades: none reported — no signal. Congressional activity: one small buy by Rep. Ro Khanna ($1K-$15K) — a weak bullish signal. Institutional: Norges Bank added a massive new $1.83B position (bullish), but Renaissance Technologies exited entirely (bearish). Two Sigma Investments more than doubled its position (+2,734%, to $53.6M) — a strong bullish signal. Cullen Capital trimmed 38% (bearish). Short interest is 56.2% of TRF volume — elevated, indicating bearish bets. The analyst bullish signal diverges from high short interest, but converges with the Norges Bank and Two Sigma institutional buys.

Documents Analyzed

Report based on filing metadata.

US Market Status